EYPT EyePoint Pharmaceuticals
- 11.870
- +0.670+5.98%
- 11.642
- -0.228-1.92%
EyePoint Pharmaceuticals News
Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating
EyePoint Pharmaceuticals (EYPT) has an average rating of buy and price targets ranging from $28 to $68, according to analysts polled by Capital IQ. Price: 11.39, Change: +0.19, Percent Change: +1.70
EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital
EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital
Express News | Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $28
Maintaining Buy Rating on EyePoint Pharmaceuticals Despite P2 Study Setback
EyePoint Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 163.39% Mizuho $39 → $30 Maintains Buy 03/08/2024 189.73% HC Wainwright & Co. $33 → $33 Maintai
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 45%
To the annoyance of some shareholders, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shares are down a considerable 45% in the last month, which continues a horrid run for the company. Looking at th
Express News | EyePoint Pharmaceuticals Inc : Mizuho Cuts Target Price to $30 From $39
Maintaining Buy Rating on EyePoint Pharmaceuticals: Strong Prospects in WAMD Market Despite NPDR Study Setback
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of Spirit Airlines, Inc. (NYSE:SAVE) fell sharply during Monday's session as the company reported a first-qu
Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.The Dow traded up 0.18% to 38,744.60 while the NASDAQ rose 0.69% to 16,267.82. The S&
Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session
Shares of Perficient, Inc (NASDAQ:PRFT) shares rose sharply during Monday's session after the company disclosed an acquisition deal and first-quarter FY24 results.The company stated that it has entere
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.The Dow traded up 0.25% to 38,772.28 while the NASDAQ rose 0.64% to 16,260.19. The S&P 500 also
EyePoint Pharmaceuticals Down Over 34%, on Pace for Largest Percent Decrease Since November 2011 -- Data Talk
EyePoint Pharmaceuticals, Inc. (EYPT) is currently at $13.00, down $6.74 or 34.14% --Would be lowest close since Dec. 1, 2023, when it closed at $6.61 --On pace for largest percent decrease since No
Biggest Stock Movers Today: Crypto Stocks, MPW, LAZR, and More
Stock futures inched higher on Monday after a soft jobs report reignited some expectations of a Federal Reserve rate cut.
Express News | EyePoint Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Down -40.9%
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
On Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2 PAVIA trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in pat
Sector Update: Health Care Stocks Gain Pre-Bell Monday
Health care stocks were gaining pre-bell Monday, with the Health Care Select Sector SPDR Fund (XLV) unchanged and the iShares Biotechnology ETF (IBB) adding 0.3%. BioNTech (BNTX) shares were down 2.6%
Market-Moving News for May 6th
EYPT: -42% | EyePoint Pharmaceuticals shares are trading lower after the company's Phase 2 PAVIA trial of DURAVYU did not meet its pre-specified primary endpoint.TCBP: 108% | XBP Europe Holdings share
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersMonogram Orthopaedics (NASDAQ:MGRM) stock increased by 19.1% to $2.31 during Monday's pre-market session. The company's market cap stands at $73.1 million. Allarity Therapeutics (NASDAQ:ALLR) s
Express News | EyePoint Pharmaceuticals Shares Are Trading Lower After the Company's Phase 2 PAVIA Trial of DURAVYU Did Not Meet Its Pre-specified Primary Endpoint
Analysis
Price Target
No Data
